Hederagenin 3-O-α-L-rhaMnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside
| 中文名称 | Hederagenin 3-O-α-L-rhaMnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside |
|---|---|
| 中文同义词 | 白头翁皂苷 D, BR;常春藤皂苷元3-O-Α-L-吡喃鼠李糖-(1→2)-Β-D-吡喃葡萄糖-(1→4)-Α-L-吡喃阿拉伯糖苷;白头翁皂苷D标准品;4补充中2;HEDERAGENIN 3-O-Α-L-RHAMNOPYRANOSYL(1→2)-(Β-D-GLUCOPYRANOSYL(1→4))-Α-L-ARABINOPYRANOSIDE(对照品 |
| 英文名称 | Hederagenin 3-O-α-L-rhaMnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside |
| 英文同义词 | Hederagenin 3-O-α-L-rhaMnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside;Pulsatilla Saponin D (90%);Pulsatilla saponin D (SB365);Olean-12-en-28-oic acid,3-[[O-6-deoxy-a-L-mannopyranosyl-(12)-O-[b-D-glucopyranosyl-(14)]-a-L-arabinopyranosyl]oxy]-23-hydroxy-, (3b,4a)-;Pulsatilla saponin D 68027-15-6;Pulsatilla saponin D, BR;Olean-12-en-28-oic acid, 3-[[O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[β-D-glucopyranosyl-(1→4)]-α-L-arabinopyranosyl]oxy]-23-hydroxy-, (3β,4α)-;Hederagenin 3-O-α-L-rhamnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside |
| CAS号 | 68027-15-6 |
| 分子式 | C47H76O17 |
| 分子量 | 913.09614 |
| EINECS号 | 211-708-6 |
| 相关类别 | 中药对照品;标准品;对照品;植提标准品;植物提取物;标准品，对照品;reagent;standard substance;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract |
| Mol文件 | 68027-15-6.mol |
| 结构式 |  |
Hederagenin 3-O-α-L-rhaMnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside 性质
| 熔点 | 239-241℃ |
|---|---|
| 沸点 | 997.6±65.0 °C(Predicted) |
| 密度 | 1.40±0.1 g/cm3 (20 ºC 760 Torr) |
| 储存条件 | Hygroscopic, -20°C Freezer, Under inert atmosphere |
| 溶解度 | 少许溶于甲醇、可溶于吡啶 |
| 酸度系数(pKa) | 4.63±0.70(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至浅米色 |
| Target | Value |
|
c-Met
() |
Pulsatilla saponin D (SB365) shows apoptotic effect accompanied by increased evidence of cleaved caspase-3 and poly (ADP ribose) polymerase.
Pulsatilla saponin D (SB365) strongly inhibits c-Met expression in gastric cancer cells.
Pulsatilla saponin D (SB365) strongly suppresses the growth and proliferation of 5 human pancreatic cancer cell lines (MIAPaCa-2, BXPC-3, PANC-1, AsPC-1 and HPAC) .
Pulsatilla saponin D (SB365) shows anti-angiogenic activity by decreasing the expression of HIF-1α and VEGF.
Pulsatilla saponin D (0.3 ng/mL to 10 μg/mL) exhibits anti-tumor activity in NSCLC cancer cells.
Cell Cytotoxicity Assay
| Cell Line: | A-549, SKMEL-2, MCF-7, and Lewis lung carcinoma (LLC) cells. |
| Concentration: | 0.3 ng/mL to 10 μg/mL. |
| Incubation Time: | 72 h. |
| Result: | Exhibited an ED 50 value of 6.3 μg/mL for A-549 cells. |
Pulsatilla saponin D (6.4 mg/kg) exhibits anti-tumor activity in Lewis lung carcinoma model.
| Animal Model: | 2x2x2 mm 3 tumor fragments of a Lewis lung carcinoma (LLC) transplanted s.c. into the auxiliary region of the BDF1 mice. |
| Dosage: | 6.4 mg/kg. |
| Administration: | Intraperitoneally on the 1 st to 7 th and 9 th to 14 th day. |
| Result: | Had such a potent antitumor effect (IR, 82 %) on a solid tumor, which is higher than Adriamycin (IR, 64%). |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/16 | S9308 | Hederagenin 3-O-α-L-rhaMnopyranosyl(1→2)-(β-D-glucopyranosyl(1→4))-α-L-arabinopyranoside Pulsatilla saponin D | 68027-15-6 | 1mg | 1286.58元 |